Trial Profile
A Multiple Dose Study to Evaluate Next Day Effects of MK-4305 on Driving Performance in Healthy Non-Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary) ; Zopiclone
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 08 Nov 2012 Results from this trial were used to support an NDA for suvorexant, which was accepted for review by the FDA in November 2012.
- 25 Jul 2012 Actual initiation date changed from May 2011 to Apr 2011 as reported by ClinicalTrials.gov.
- 20 Dec 2011 Actual end date (November 2011) added as reported by ClinicalTrials.gov.